4-(7-甲基咪唑[1,2-a]吡啶)苯胺 | 64730-34-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(7-甲基咪唑[1,2-a]吡啶)苯胺
• 中文别名: 4-(7-甲基咪唑并[1,2-A]吡啶-2-基)苯胺
• 英文名称: 7-methyl-2-(4-aminophenyl)imidazo-[1,2-a]pyridine
• 英文别名: 4-(7-Methylimidazo[1,2-a]pyridin-2-yl)aniline
• CAS: 64730-34-3
• 化学式: C₁₄H₁₃N₃
• 分子量: 223.277
• InChiKey: ZMLUDLQZWAWHGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  43.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-(7-甲基咪唑[1,2-a]吡啶)苯胺 、 5-叔丁基-3-异氰酰基异噁唑 以 氯仿 为溶剂， 反应 2.0h， 生成 N-(5-(tert-butyl)isoxazol-3-yl)-N'-(4-(7-methylimidazo[1,2-a]pyridin-2-yl)phenyl)urea
  参考文献：
  名称：

  Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N′-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo

  摘要：

  FLT3 inhibitors have been explored as a viable therapy for acute myeloid leukemia (AML). However, the clinical outcomes of these FLT3 inhibitors were underwhelming except AC220. Therefore, the development of novel FLT3 inhibitors with high potency against both FLT3-WT and FLT3-ITD mutants are strongly demanded at the present time. In this study, we designed and synthesized a series of novel N-(5-(tert-butyl) isoxazol-3-yl)-N'-phenylurea derivatives as FLT3 inhibitors. SAR studies focused on the fused rings led to the discovery of a series of compounds with high potency against FLT3-ITD-bearing MV4-11 cells and significantly inhibitory activity toward FLT3. Among these compounds, N-(5-(tert-butyl) isoxazol-3-yl)-N'-(4-(7-methoxyimidazo[1,2-a]pyridin-2-yl)phenyl) urea (16i), displayed acceptable aqueous solubility, desirable pharmacokinetic profile and high cytotoxicity selectivity against MV4-11 cells. This compound can inhibit phosphorylation of FLT3 and induce apoptosis in a concentration-dependent manner. Further in vivo antitumor studies showed that 16i led to complete tumor regression in the MV4-11 xenograft model at a dose of 60 mg/kg/d while without observable body weight loss. This study had provided us a new chemotype of FLT3 inhibitors as novel therapic candidates for AML. (C) 2015 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2015.06.033
• 作为产物：
  描述：

  2-氨基-4-甲基吡啶 在 镍 氢溴酸 、 氢气 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 4-(7-甲基咪唑[1,2-a]吡啶)苯胺
  参考文献：
  名称：

  2-芳基和2-芳氧基甲基咪唑并[1,2- a ]吡啶的制备及相关化合物

  摘要：

  一系列取代的2-芳基咪唑并[1,2-α]吡啶已被制备，其中多种取代基被引入在苯环的4'位和在3，5的，6或7位杂环。大多数实例在4'-位具有乙酰氨基，溴，氰基或甲酰基取代基。还已经制备了类似的咪唑并[ 2，1- b ]噻唑和咪唑并[1,2- a ]嘧啶。制备了由咪唑的4'-甲酰基苯氧基甲基衍生物，吡啶，噻唑，苯并咪唑和环取代的咪唑并[1,2- a ]吡啶的三个位置异构体组成的另一系列化合物。还制备了咪唑和咪唑并[1,2- a ]吡啶的2-（4'-甲酰基苯基乙烯基）衍生物。

  DOI：

  10.1002/jhet.5570250119

文献信息

• Imidazo-heterocyclic compounds and pharmaceutical composition comprising
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04621084A1

  公开（公告）日：1986-11-04

  New imidazo-heterocyclic compounds of the formula: ##STR1## wherein R.sup.1 is hydrogen, lower alkyl or halogen, R.sup.2 is hydrogen, lower alkyl, halogen, aminomethyl optionally substituted with lower alkyl, or piperazin-1-yl-methyl optionally substituted with lower alkyl, R.sup.3 is a partially suturated heterocyclic group selected from benzothiazolinyl, benzoxazolinyl, benzimidazolinyl, 3,4-dihydro-2H-1,4-benzothiazinyl, 3,4-dihydro-2H-1,4-benzoxazinyl and 1,2,3,4-tetrahydroquinoxalinyl, which is substituted with oxo, thioxo, imino or lower alkylimino, and which may be substituted with lower alkyl optionally substituted with lower alkanoyloxy, lower alkoxycarbonyl, pyridyl or lower alkylamino; or an unsaturated heterocyclic group selected from benzoxazolyl and benzimidazolyl, which may be substituted with lower alkyl or pyridyl(lower)alkylthio, and Y is .dbd.N-- or a group of the formula: ##STR2## in which R.sup.4 is hydrogen, hydroxy, lower alkyl, lower alkoxy or ar(lower)alkoxy, and pharmaceutically acceptable salts thereof, and processes for preparation thereof and pharmaceutical composition comprising the same. These derivatives and pharmaceutically acceptable salts thereof are useful as cardiotonic agents and untiulcer agents.

  新的咪唑-杂环化合物的化学式翻译如下：其中R.sup.1为氢、较低的烷基或卤素，R.sup.2为氢、较低的烷基、卤素、氨甲基（可选择性地取代为较低的烷基）或哌嗪-1-基甲基（可选择性地取代为较低的烷基），R.sup.3为从苯并噻唑基、苯并噁唑基、苯并咪唑基、3,4-二氢-2H-1,4-苯并噻唑基、3,4-二氢-2H-1,4-苯并噁唑基和1,2,3,4-四氢喹喔啉基中选择的部分饱和杂环基，该基取代为氧代、硫代、亚胺或较低的烷基亚胺，并且可以取代为可选择性地取代为较低的烷基、可选择性地取代为较低的烷酰氧基、较低的烷氧羰基、吡啶基或较低的烷基氨基；或从苯并噁唑基和苯并咪唑基中选择的不饱和杂环基，该基可以取代为较低的烷基或吡啶基（较低）烷基硫基，Y为.dbd.N--或化学式的一个基团：其中R.sup.4为氢、羟基、较低的烷基、较低的烷氧基或芳基（较低）烷氧基，以及其药学上可接受的盐，以及其制备方法和包含它们的药物组合物。这些衍生物及其药学上可接受的盐可用作心力衰竭药物和抗溃疡药物。
• Beneficial effects of a new neuroprotective compound in neuronal cells and MPTP-administered mouse model of Parkinson's disease
  作者：Izumi Kato、Yudai Ogawa、Fumika Yakushiji、Jiro Ogura、Masaki Kobayashi、Naoya Shindo、Satoshi Ichikawa、Katsumi Maenaka、Masahiro Sakaitani

  DOI：10.1039/d3cc03069e

  日期：——

  A new compound, a derivative of 3,4,5-trimethoxy-N-phenyl benzamide bearing an 8′′-methylimidazopyridine moiety, is found to demonstrate neuroprotective effects by preventing cell death caused by oxidative stress.

  研究发现，一种带有 8′′-甲基咪唑并吡啶分子的 3,4,5-三甲氧基-N-苯基苯甲酰胺衍生物具有神经保护作用，可防止氧化应激导致的细胞死亡。
• Synthesis and biological evaluation of imidazo[1,2-a]pyrimidines and imidazo[1,2-a]pyridines as new inhibitors of the Wnt/β-catenin signaling
  作者：Barbara Cosimelli、Sonia Laneri、Carmine Ostacolo、Antonia Sacchi、Elda Severi、Elena Porcù、Elena Rampazzo、Enrico Moro、Giuseppe Basso、Giampietro Viola

  DOI：10.1016/j.ejmech.2014.05.071

  日期：2014.8

  Wnt/β-catenin signaling plays an important role in the regulation of embryonic development and tumorigenesis. Since its deregulation results in severe human diseases, especially cancer, the Wnt signaling pathway constitutes a promising platform for pharmacological targeting of cancer. In this study we synthesized a series of imidazo[1,2-a]pyrimidines and imidazo[1,2-a]pyridines and identified some derivatives that were able to inhibit the Wnt/β-catenin signaling pathway in a luciferase reporter assay and cell proliferation in selected cancer cell lines, endowed with APC or β-catenin gene mutations. The most active compounds significantly downregulate the expression of Wnt target genes such as c-myc and cyclin D1. Further studies indicated that these compounds function independently of GSK-3β activity. More importantly, in vivo experiments, carried out on a Wnt-reporter zebrafish model indicate, in particular for compounds 4c and 4i as the most active compounds, an activity comparable to that of the reference compound IWR1, suggesting their potential use not only as small molecule inhibitors of the Wnt/β-catenin signal in Wnt driven cancers, but also in other Wnt-related diseases.
• Imidazo-heterocyclic compounds, processes for preparation thereof and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0120589B1

  公开（公告）日：1988-06-08
• US4621084A
  申请人：——

  公开号：US4621084A

  公开（公告）日：1986-11-04